Compare Target Corporation (TGT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Target Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? Target Corporation trades at $157.66 (market cap $69.05B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Target Corporation is far larger — about 13.8× Travere Therapeutics Inc. Common Stock's market cap, and Target Corporation pays a 3.05% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Target Corporation for 137 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TGT | TVTX | |
|---|---|---|
Market Cap | $69.05B | $5.02B |
Volume | 3,728,482 | 2,060,842 |
Sector | Consumer Staples | Health |
52-Week High | $169.90 | $67.52 |
52-Week Low | $83.68 | $26.79 |
Typical Hold Time | 137 Days | 0 Days |
Enterprise Value | $82.33B | $5.15B |
Dividend Yield | 3.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Target Corporation (TGT) trades at $151.98, down 1.04% on the day, with a neutral technical outlook. The stock shows strong fundamentals with a P/E of 15.77 and consistent earnings beats in recent quarters. Recent news highlights Target's holiday price-cutting strategy to capture market share, while analyst consensus remains positive with a $166.95 price target.
Target presents a balanced investment case with solid profitability metrics (ROE 26.41%) and stable cash flow generation. Near-term catalysts include holiday sales performance and margin benefits from tariff refunds. Key risks include competitive pressures and consumer spending volatility. Wall Street maintains a bullish bias with 47% buy ratings.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
